Press release
Acne Vulgaris Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Acne Vulgaris Treatment Landscape @ Acne Vulgaris Pipeline Outlook [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Acne Vulgaris Pipeline Report
* On July 3, 2025, Biofrontera Bioscience GmbH initiated a study to examine the safety and efficacy of photodynamic therapy (PDT) using Ameluz Registered in combination with the PDT-lamp BF-RhodoLED Registered . The trial compares this approach against a placebo treatment in patients with moderate to severe acne vulgaris.
* On July 9, 2025, Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd . initiated a clinical study to evaluate the safety and efficacy of clascoterone cream, 1%, compared to a vehicle cream. The treatment is applied twice daily over 12 weeks in patients suffering from facial acne vulgaris.
* On July 17, 2025, Sun Pharmaceutical Industries Limited launched a study focusing on Winlevi, recognized as the first topical anti-androgen and sebum inhibitor approved for acne vulgaris. Since no prior trials have investigated its use in combination therapies, this study is assessing Winlevi together with Duac gel to better replicate real-world clinical practice.
* DelveInsight's Acne Vulgaris pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Acne Vulgaris treatment.
* The leading Acne Vulgaris Companies such as Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.
* Promising Acne Vulgaris Pipeline Therapies such as Clascoterone, S6G5T-3, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide, Hydrogen Peroxide, gevokizumab, BLI1100 and others.
Discover groundbreaking developments in Acne Vulgaris Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Acne Vulgaris Ongoing Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Acne Vulgaris Emerging Drugs Profile
* Berdazimer sodium (SB 204): Pelthos Therapeutics
SB204 is a first-in-class nitric oxide (NO)-releasing topical treatment monotherapy. The Phase 2b study demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and inflammatory (larger red bumps and pustules) lesions at Week 12 with all doses of SB204 compared to vehicle. SB204 demonstrated excellent cutaneous tolerability with no treatment-related serious adverse events in over 400 dosed subjects to date. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.
* DMT310: Dermata Therapeutics
DMT310 is a lead product candidate, developed from our Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.
* GT 20029 : Suzhou Kintor Pharmaceuticals
GT-20029 is a small molecule that works on Androgen receptor degradation enhancer's mechanism of action. It is administered through topical route as gel/tincture form. The drug candidate acts by targeting androgen receptor and cereblon (CRBN). It is being developed based on PROTAC (Protein Degradation Targeting Chimera) technology. Currently, the drug is in Phase I stage of its development for the treatment of acne vulgaris.
The Acne Vulgaris Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Acne Vulgaris with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acne Vulgaris Treatment.
* Acne Vulgaris Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Acne Vulgaris Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acne Vulgaris market
Stay informed about the Acne Vulgaris pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acne Vulgaris Unmet Needs [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Acne Vulgaris Companies
Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.
Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Acne Vulgaris Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Acne Vulgaris Pipeline! See the latest progress in drug development and clinical research @ Acne Vulgaris Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Acne Vulgaris Pipeline Report
* Coverage- Global
* Acne Vulgaris Companies- Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.
* Acne Vulgaris Pipeline Therapies- Clascoterone, S6G5T-3, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide, Hydrogen Peroxide, gevokizumab, BLI1100 and others.
* Acne Vulgaris Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acne Vulgaris Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Infectious Diseases Research-Access the Full Acne Vulgaris Pipeline Analysis Today! @ Acne Vulgaris Drugs and Companies [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Acne Vulgaris: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acne Vulgaris- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Berdazimer sodium (SB 204) : Pelthos Therapeutics
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Early Stage Products (Phase I/II)
* GT 20029 : Suzhou Kintor Pharmaceuticals
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Acne Vulgaris Key Companies
* Acne Vulgaris Key Products
* Acne Vulgaris- Unmet Needs
* Acne Vulgaris- Market Drivers and Barriers
* Acne Vulgaris- Future Perspectives and Conclusion
* Acne Vulgaris Analyst Views
* Acne Vulgaris Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acne-vulgaris-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acne Vulgaris Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 4150785 • Views: …
More Releases from ABNewswire
What are the most effective medical therapies for managing excess body mass? Reg …
Cape Coral healthcare providers report breakthrough success using FDA-approved GLP-1 medications for weight management, with Premier Wellness Florida leading comprehensive treatment programs combining pharmaceuticals with holistic wellness support.
Cape Coral, FL - Recent clinical developments in medical weight management have prompted Southwest Florida healthcare providers to report significant patient success rates with FDA-approved medications and comprehensive treatment protocols. Premier Wellness Florida, operating from its Del Prado Boulevard facility, has documented patient…
Winkler Kurtz LLP - Long Island Lawyers Port Jefferson Station Injury Attorney O …
Winkler Kurtz LLP is a leading Long Island law firm specializing in personal injury cases such as car accidents, slip and falls, and medical malpractice. Offering decades of local experience, the firm provides compassionate support and skilled legal advocacy to help injury victims secure justice and compensation. With free consultations and a contingency fee policy, Winkler Kurtz LLP ensures quality legal help is available to all Long Islanders in need.
When…
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
More Releases for Acne
Expanding Acne Rates Support Global Anti-Acne Dermal Patch Market Expansion
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during the forecast period, 2023-2032.
Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR
This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the…
Expanding Acne Rates Support Global Anti-Acne Dermal Patch Market Expansion
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during 2023-2032.
Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR
This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the aspects of this comprehensive…
Growing Acne Incidences Benefiting Global Anti-Acne Dermal Patch Market Developm …
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during 2023-2032.
Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR
This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the aspects of this comprehensive…
Expanding Acne Rates Support Global Anti-Acne Dermal Patch Market Expansion
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during 2023-2032.
Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR
This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the aspects of…
Rising Cases of Acne Boosting Professional Acne Treatment Market Growth
Factor such as the rising cases of acne, surging adoption of acne treatments, growing healthcare spending, increasing disposable income, sedentary lifestyle, strong product pipeline, and mounting number of research programs are expected to propel the professional acne treatment market at a CAGR of 7.6% during 2020–2030. According to P&S Intelligence, the market size is expected to reach $13,124.5 million by 2030 from $6,298.9 million in 2020. Moreover, the market is…
Global Market Study on Acne Treatment Inflammatory Acne Segment Anticipated.
The global acne treatment market is stagnant in terms of incremental innovation as most players are investing in product reformulation instead of new product development. The analysts of Persistence Market Research have come up with a new publication titled “Acne Treatment Market: Global Industry Analysis and Forecast, 2017 – 2025,” and have observed that the North America region is expected to witness significant growth in market revenue due to rising affinity…
